Altered arginine metabolism in the central nervous system (CNS) of the Cln3-/- mouse model of juvenile Batten disease

Neuropathology and Applied Neurobiology

Volumn 35, Issue 2, 2009, Pages 189-207

  Chan, C H ^a   Ramirez Montealegre, D ^a   Pearce, D A ^a,b  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Arginine; Batten disease; CLN3; JNCL; Lysosome; Nitric xoide

Indexed keywords

AMINO ACID; ARGINASE; ARGININE; CARBAMOYL PHOSPHATE SYNTHASE; CARBON 14; CITRULLINE; COMPLEMENTARY DNA; GENOMIC DNA; LIVER ENZYME; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; ORNITHINE CARBAMOYLTRANSFERASE; RNA; UREA;

AMINO ACID METABOLISM; AMINO ACID TRANSPORT; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; BRAIN; BRAIN CORTEX; CENTRAL NERVOUS SYSTEM; CEREBELLUM; CHILDHOOD DISEASE; DEGENERATIVE DISEASE; ENZYME ASSAY; GENE EXPRESSION; GENE MUTATION; GENETIC DISORDER; GRANULE CELL; IMMUNOBLOTTING; LYSOSOME; METABOLITE; MOUSE; NEUROLOGIC DISEASE; NEURONAL CEROID LIPOFUSCINOSIS; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UREA CYCLE; WESTERN BLOTTING;

ANIMALS; ARGININE; BRAIN; CATIONIC AMINO ACID TRANSPORTER 1; CELLS, CULTURED; CITRULLINE; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION; LIVER; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, KNOCKOUT; MOLECULAR CHAPERONES; NEURONAL CEROID-LIPOFUSCINOSES; NEURONS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN ISOFORMS; RNA, MESSENGER; UREA;

EID: 61849166008     PISSN: 03051846     EISSN: 13652990     Source Type: Journal    
DOI: 10.1111/j.1365-2990.2008.00984.x     Document Type: Article

References (89)

1. Cooper JD. Progress towards understanding the neurobiology of Batten disease or neuronal ceroid lipofuscinosis. Curr Opin Neurol 2003 16 : 121 8
2. Mole SE. The genetic spectrum of human neuronal ceroid-lipofuscinoses. Brain Pathol 2004 14 : 70 6
3. Ezaki J, Takeda-Ezaki M, Koike M, Ohsawa Y, Taka H, Mineki R, Murayama K, Uchiyama Y, Ueno T, Kominami E. Characterization of Cln3p, the gene product responsible for juvenile neuronal ceroid lipofuscinosis, as a lysosomal integral membrane glycoprotein. J Neurochem 2003 87 : 1296 308
4. Jarvela I, Sainio M, Rantamaki T, Olkkonen VM, Carpen O, Peltonen L, Jalanko A. Biosynthesis and intracellular targeting of the CLN3 protein defective in Batten disease. Hum Mol Genet 1998 7 : 85 90
5. Jarvela I, Lehtovirta M, Tikkanen R, Kyttala A, Jalanko A. Defective intracellular transport of CLN3 is the molecular basis of Batten disease (JNCL). Hum Mol Genet 1999 8 : 1091 8
6. Katz ML, Gao CL, Prabhakaram M, Shibuya H, Liu PC, Johnson GS. Immunochemical localization of the Batten disease (CLN3) protein in retina. Invest Ophthalmol Vis Sci 1997 38 : 2375 86
7. Kremmidiotis G, Lensink IL, Bilton RL, Woollatt E, Chataway TK, Sutherland GR, Callen DF. The Batten disease gene product (CLN3p) is a Golgi integral membrane protein. Hum Mol Genet 1999 8 : 523 31
8. Kyttala A, Ihrke G, Vesa J, Schell MJ, Luzio JP. Two motifs target Batten disease protein CLN3 to lysosomes in transfected nonneuronal and neuronal cells. Mol Biol Cell 2004 15 : 1313 23
9. Luiro K, Kopra O, Lehtovirta M, Jalanko A. CLN3 protein is targeted to neuronal synapses but excluded from synaptic vesicles: new clues to Batten disease. Hum Mol Genet 2001 10 : 2123 31
10. Margraf LR, Boriack RL, Routheut AA, Cuppen I, Alhilali L, Bennett CJ, Bennett MJ. Tissue expression and subcellular localization of CLN3, the Batten disease protein. Mol Genet Metab 1999 66 : 283 9
11. Mao Q, Xia H, Davidson BL. Intracellular trafficking of CLN3, the protein underlying the childhood neurodegenerative disease, Batten disease. FEBS Lett 2003 555 : 351 7
12. Persaud-Sawin DA, McNamara JO, Rylova S, Vandongen A, Boustany RM. A galactosylceramide binding domain is involved in trafficking of CLN3 from Golgi to rafts via recycling endosomes. Pediatr Res 2004 56 : 449 63
13. Golabek AA, Kida E, Walus M, Kaczmarski W, Michalewski M, Wisniewski KE. CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells. Mol Genet Metab 2000 70 : 203 13
14. Holopainen JM, Saarikoski J, Kinnunen PK, Jarvela I. Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs). Eur J Biochem 2001 268 : 5851 6
15. Luiro K, Yliannala K, Ahtiainen L, Maunu H, Jarvela I, Kyttala A, Jalanko A. Interconnections of CLN3, Hook1 and Rab proteins link Batten disease to defects in the endocytic pathway. Hum Mol Genet 2004 13 : 3017 27
16. Luiro K, Kopra O, Blom T, Gentile M, Mitchison HM, Hovatta I, Tornquist K, Jalanko A. Batten disease (JNCL) is linked to disturbances in mitochondrial, cytoskeletal, and synaptic compartments. J Neurosci Res 2006 84 : 1124 38
17. Narayan SB, Rakheja D, Pastor JV, Rosenblatt K, Greene SR, Yang J, Wolf BA, Bennett MJ. Over-expression of CLN3P, the Batten disease protein, inhibits PANDER-induced apoptosis in neuroblastoma cells: further evidence that CLN3P has anti-apoptotic properties. Mol Genet Metab 2006 88 : 178 83
18. Persaud-Sawin DA, Vandongen A, Boustany RM. Motifs within the CLN3 protein: modulation of cell growth rates and apoptosis. Hum Mol Genet 2002 11 : 2129 42
19. Ramirez-Montealegre D, Pearce DA. Defective lysosomal arginine transport in juvenile Batten disease. Hum Mol Genet 2005 14 : 3759 73
20. Pearce DA, Sherman F. BTN1, a yeast gene corresponding to the human gene responsible for Batten's disease, is not essential for viability, mitochondrial function, or degradation of mitochondrial ATP synthase. Yeast 1997 13 : 691 7
21. Pearce DA, Ferea T, Nosel SA, Das B, Sherman F. Action of BTN1, the yeast orthologue of the gene mutated in Batten disease. Nat Genet 1999 22 : 55 8
22. Kim Y, Ramirez-Montealegre D, Pearce DA. A role in vacuolar arginine transport for yeast Btn1p and for human CLN3, the protein defective in Batten disease. Proc Natl Acad Sci USA 2003 100 : 15458 62
23. Padilla-Lopez S, Pearce DA. Saccharomyces cerevisiae lacking Btn1p modulate vacuolar ATPase activity to regulate pH imbalance in the vacuole. J Biol Chem 2006 281 : 10273 80
24. Mitchison HM, Bernard DJ, Greene ND, Cooper JD, Junaid MA, Pullarkat RK, de Vos N, Breuning MH, Owens JW, Mobley WC, Gardiner RM, Lake BD, Taschner PE, Nussbaum RL. Targeted disruption of the Cln3 gene provides a mouse model for Batten disease. The Batten Mouse Model Consortium [corrected Neurobiol Dis 1999 6 : 321 34
25. Corraliza IM, Campo ML, Soler G, Modolell M. Determination of arginase activity in macrophages: a micromethod. J Immunol Methods 1994 174 : 231 5
26. O'Brien WE. A continuous spectrophotometric assay for argininosuccinate synthetase based on pyrophosphate formation. Anal Biochem 1976 76 : 423 30
27. Nuzum CT, Snodgrass PJ. Multiple assays of the five urea-cycle enzymes in human liver homogenates. In The Urea Cycle. Eds S Grisolia, R Baguena, F Major. New York, NY : John Wiley & Sons, 1976 325 49
28. Ye X, Robinson MB, Batshaw ML, Furth EE, Smith I, Wilson JM. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem 1996 271 : 3639 46
29. Pierson DL. A rapid colorimetric assay for carbamyl phosphate synthetase I. J Biochem Biophys Methods 1980 3 : 31 7
30. Pfaffl MW, Horgan GW, Dempfle L. Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002 30 : e36
31. + (CAT-1) amino acid transporter as detected by immunohistochemistry. Am J Physiol 1994 266 : 817 24
32. Kovacs AD, Weimer JM, Pearce DA. Selectively increased sensitivity of cerebellar granule cells to AMPA receptor-mediated excitotoxicity in a mouse model of Batten disease. Neurobiol Dis 2006 22 : 575 85
33. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol 2002 67 : 259 79
34. Cohn RM, Roth KS. Hyperammonemia, bane of the brain. Clin Pediatr (Phila) 2004 43 : 683 9
35. Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog Neurobiol 2001 64 : 365 91
36. Bredt DS, Ferris CD, Snyder SH. Nitric oxide synthase regulatory sites. Phosphorylation by cyclic AMP-dependent protein kinase, protein kinase C, and calcium/calmodulin protein kinase; identification of flavin and calmodulin binding sites. J Biol Chem 1992 267 : 10976 81
37. Komeima K, Hayashi Y, Naito Y, Watanabe Y. Inhibition of neuronal nitric-oxide synthase by calcium/ calmodulin-dependent protein kinase IIalpha through Ser847 phosphorylation in NG108-15 neuronal cells. J Biol Chem 2000 275 : 28139 43
38. Gerlach M, Blum-Degen D, Ransmayr G, Leblhuber F, Pedersen V, Riederer P. Expression, but not activity, of neuronal nitric oxide synthase is regionally increased in the alcoholic brain. Alcohol Alcohol 2001 36 : 65 9
39. Liu P, Smith PF, Appleton I, Darlington CL, Bilkey DK. Nitric oxide synthase and arginase in the rat hippocampus and the entorhinal, perirhinal, postrhinal, and temporal cortices: regional variations and age-related changes. Hippocampus 2003 13 : 859 67
40. Liu P, Smith PF, Appleton I, Darlington CL, Bilkey DK. Age-related changes in nitric oxide synthase and arginase in the rat prefrontal cortex. Neurobiol Aging 2004 25 : 547 52
41. Liu P, Smith PF, Appleton I, Darlington CL, Bilkey DK. Hippocampal nitric oxide synthase and arginase and age-associated behavioral deficits. Hippocampus 2005 15 : 642 55
42. Hayashi Y, Nishio M, Naito Y, Yokokura H, Nimura Y, Hidaka H, Watanabe Y. Regulation of neuronal nitric-oxide synthase by calmodulin kinases. J Biol Chem 1999 274 : 20597 602
43. Rameau GA, Chiu LY, Ziff EB. Bidirectional regulation of neuronal nitric-oxide synthase phosphorylation at serine 847 by the N-methyl-D-aspartate receptor. J Biol Chem 2004 279 : 14307 14
44. Chattopadhyay S, Ito M, Cooper JD, Brooks AI, Curran TM, Powers JM, Pearce DA. An autoantibody inhibitory to glutamic acid decarboxylase in the neurodegenerative disorder Batten disease. Hum Mol Genet 2002 11 : 1421 31
45. Pears MR, Cooper JD, Mitchison HM, Mortishire-Smith RJ, Pearce DA, Griffin JL. High resolution 1H NMR-based metabolomics indicates a neurotransmitter cycling deficit in cerebral tissue from a mouse model of Batten disease. J Biol Chem 2005 280 : 42508 14
46. Pearce DA, McCall K, Mooney RA, Chattopadhyay S, Curran TM. Altered amino acid levels in sera of a mouse model for juvenile neuronal ceroid lipofuscinoses. Clin Chim Acta 2003 332 : 145 8
47. Rameau GA, Chiu LY, Ziff EB. NMDA receptor regulation of nNOS phosphorylation and induction of neuron death. Neurobiol Aging 2003 24 : 1123 33
48. Nardocci N, Verga ML, Binelli S, Zorzi G, Angelini L, Bugiani O. Neuronal ceroid-lipofuscinosis: a clinical and morphological study of 19 patients. Am J Med Genet 1995 57 : 137 41
49. Autti T, Raininko R, Vanhanen SL, Santavuori P. MRI of neuronal ceroid lipofuscinosis. I. Cranial MRI of 30 patients with juvenile neuronal ceroid lipofuscinosis. Neuroradiology 1996 38 : 476 82
50. Closs EI, Simon A, Vekony N, Rotmann A. Plasma membrane transporters for arginine. J Nutr 2004 134 : 2752S 9S
51. Kim JW, Closs EI, Albritton LM, Cunningham JM. Transport of cationic amino acids by the mouse ecotropic retrovirus receptor. Nature 1991 352 : 725 8
52. Hosokawa H, Sawamura T, Kobayashi S, Ninomiya H, Miwa S, Masaki T. Cloning and characterization of a brain-specific cationic amino acid transporter. J Biol Chem 1997 272 : 8717 22
53. Ito K, Groudine M. A new member of the cationic amino acid transporter family is preferentially expressed in adult mouse brain. J Biol Chem 1997 272 : 26780 6
54. Garthwaite J, Boulton CL. Nitric oxide signaling in the central nervous system. Annu Rev Physiol 1995 57 : 683 706
55. Szabo C. Physiological and pathophysiological roles of nitric oxide in the central nervous system. Brain Res Bull 1996 41 : 131 41
56. Prast H, Philippu A. Nitric oxide as modulator of neuronal function. Prog Neurobiol 2001 64 : 51 68
57. Holan V, Krulova M, Zajicova A, Pindjakova J. Nitric oxide as a regulatory and effector molecule in the immune system. Mol Immunol 2002 38 : 989 95
58. Bronte V, Zanovello P. Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 2005 5 : 641 54
59. Guix FX, Uribesalgo I, Coma M, Munoz FJ. The physiology and pathophysiology of nitric oxide in the brain. Prog Neurobiol 2005 76 : 126 52
60. Moncada S, Bolanos JP. Nitric oxide, cell bioenergetics and neurodegeneration. J Neurochem 2006 97 : 1676 89
61. Vitiello SP, Wolfe DM, Pearce DA. Absence of Btn1p in the yeast model for juvenile Batten disease may cause arginine to become toxic to yeast cells. Hum Mol Genet 2007 16 : 1007 16
62. Weimer JM, Chattopadhyay S, Custer AW, Pearce DA. Elevation of Hook1 in a disease model of Batten disease does not affect a novel interaction between Ankyrin G and Hook1. Biochem Biophys Res Commun 2005 330 : 1176 81
63. Zharikov SI, Block ER. Association of L-arginine transporters with fodrin: implications for hypoxic inhibition of arginine uptake. Am J Physiol Lung Cell Mol Physiol 2000 278 : L111 17
64. Zharikov SI, Sigova AA, Chen S, Bubb MR, Block ER. Cytoskeletal regulation of the L-arginine/NO pathway in pulmonary artery endothelial cells. Am J Physiol Lung Cell Mol Physiol 2001 280 : L465 73
65. Huang Y, Kang BN, Tian J, Liu Y, Luo HR, Hester L, Snyder SH. The cationic amino acid transporters CAT1 and CAT3 mediate NMDA receptor activation-dependent changes in elaboration of neuronal processes via the mammalian target of rapamycin mTOR pathway. J Neurosci 2007 27 : 449 58
66. Cao Y, Espinola JA, Fossale E, Massey AC, Cuervo AM, MacDonald ME, Cotman SL. Autophagy is disrupted in a knock-in mouse model of juvenile neuronal ceroid lipofuscinosis. J Biol Chem 2006 281 : 20483 93
67. Osorio NS, Carvalho A, Almeida AJ, Padilla-Lopez S, Leao C, Laranjinha J, Ludovico P, Pearce DA, Rodrigues F. Nitric oxide signaling is disrupted in the yeast model for Batten disease. Mol Biol Cell 2007 18 : 2755 67
68. Baader SL, Schilling K. Glutamate receptors mediate dynamic regulation of nitric oxide synthase expression in cerebellar granule cells. J Neurosci 1996 16 : 1440 9
69. Tascedda F, Molteni R, Racagni G, Riva MA. Acute and chronic changes in K(+)-induced depolarization alter NMDA and nNOS gene expression in cultured cerebellar granule cells. Brain Res Mol Brain Res 1996 40 : 171 4
70. Baader SL, Bucher S, Schilling K. The developmental expression of neuronal nitric oxide synthase in cerebellar granule cells is sensitive to GABA and neurotrophins. Dev Neurosci 1997 19 : 283 90
71. Boissel JP, Schwarz PM, Forstermann U. Neuronal-type NO synthase: transcript diversity and expressional regulation. Nitric Oxide 1998 2 : 337 49
72. Forstermann U, Boissel JP, Kleinert H. Expressional control of the 'constitutive' isoforms of nitric oxide synthase (NOS I and NOS III). FASEB J 1998 12 : 773 90
73. Newton DC, Bevan SC, Choi S, Robb GB, Millar A, Wang Y, Marsden PA. Translational regulation of human neuronal nitric-oxide synthase by an alternatively spliced 5′-untranslated region leader exon. J Biol Chem 2003 278 : 636 44
74. Nakane M, Mitchell J, Forstermann U, Murad F. Phosphorylation by calcium calmodulin-dependent protein kinase II and protein kinase C modulates the activity of nitric oxide synthase. Biochem Biophys Res Commun 1991 180 : 1396 402
75. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990 87 : 682 5
76. Hallemeesch MM, Lamers WH, Deutz NE. Reduced arginine availability and nitric oxide production. Clin Nutr 2002 21 : 273 9
77. Wu G, Morris SM Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998 336 (Pt 1 1 17
78. Mori M, Gotoh T. Regulation of nitric oxide production by arginine metabolic enzymes. Biochem Biophys Res Commun 2000 275 : 715 19
79. Estevez AG, Sahawneh MA, Lange PS, Bae N, Egea M, Ratan RR. Arginase 1 regulation of nitric oxide production is key to survival of trophic factor-deprived motor neurons. J Neurosci 2006 26 : 8512 16
80. Contestabile A. Roles of NMDA receptor activity and nitric oxide production in brain development. Brain Res Brain Res Rev 2000 32 : 476 509
81. Dawson VL, Dawson TM, London ED, Bredt DS, Snyder SH. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc Natl Acad Sci USA 1991 88 : 6368 71
82. Dalkara T, Endres M, Moskowitz MA. Mechanisms of NO neurotoxicity. Prog Brain Res 1998 118 : 231 9
83. Bishop A, Anderson JE. NO signaling in the CNS: from the physiological to the pathological. Toxicology 2005 208 : 193 205
84. Brooks AI, Chattopadhyay S, Mitchison HM, Nussbaum RL, Pearce DA. Functional categorization of gene expression changes in the cerebellum of a Cln3-knockout mouse model for Batten disease. Mol Genet Metab 2003 78 : 17 30
85. Elshatory Y, Brooks AI, Chattopadhyay S, Curran TM, Gupta P, Ramalingam V, Hofmann SL, Pearce DA. Early changes in gene expression in two models of Batten disease. FEBS Lett 2003 538 : 207 12
86. Chattopadhyay S, Kingsley E, Serour A, Curran TM, Brooks AI, Pearce DA. Altered gene expression in the eye of a mouse model for batten disease. Invest Ophthalmol Vis Sci 2004 45 : 2893 905
87. Hobert JA, Dawson G. A novel role of the Batten disease gene CLN3: association with BMP synthesis. Biochem Biophys Res Commun 2007 358 : 111 16
88. Narayan SB, Tan L, Bennett MJ. Intermediate levels of neuronal palmitoyl-protein Delta-9 desaturase in heterozygotes for murine Batten disease. Mol Genet Metab 2008 93 : 89 91
89. Kakela R, Somerharju P, Tyynela J. Analysis of phospholipid molecular species in brains from patients with infantile and juvenile neuronal-ceroid lipofuscinosis using liquid chromatography-electrospray ionization mass spectrometry. J Neurochem 2003 84 : 1051 65